Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →For weight loss, the FDA-approved Zepbound label lists tirzepatide 2.5 mg injected once weekly for 4 weeks, then 2.5 mg increases after at least 4 weeks on the current dose, as tolerated, up to 15 mg once weekly [1]. Compounded tirzepatide is not FDA-approved and requires clinician-directed prescribing [8].
| Weeks on therapy | FDA-labeled Zepbound dose step | How providers commonly read this reference |
|---|---|---|
| Weeks 1–4 | 2.5 mg once weekly [1] | The FDA label describes this as the starting dose for treatment initiation, not a maintenance dose [1]. |
| Weeks 5–8 | 5 mg once weekly [1] | The FDA label lists 5 mg once weekly as the first maintenance dose for chronic weight management [1]. |
| Weeks 9–12 | 7.5 mg once weekly, if clinically appropriate [1] | The FDA label allows 2.5 mg dose increases after at least 4 weeks on the current dose [1]. |
| Weeks 13–16 | 10 mg once weekly [1] | The FDA label lists 10 mg once weekly as a maintenance dose for chronic weight management [1]. |
| Weeks 17–20 | 12.5 mg once weekly, if clinically appropriate [1] | The FDA label allows this step before 15 mg once weekly [1]. |
| Week 21 and after | 15 mg once weekly [1] | The FDA label lists 15 mg once weekly as a maintenance dose and the maximum dose [1]. |
Quick facts: tirzepatide dosing at a glance
Tirzepatide dosing is built around slow titration, with at least 4 weeks at each labeled step before a possible increase [1]. This helps clinicians balance weight response with side effects such as nausea, vomiting, diarrhea, constipation, abdominal pain, dehydration risk, and low blood sugar risk when used with insulin or sulfonylureas [1].
| Dosing point | FDA-label information | Safety note |
|---|---|---|
| Starting dose | The FDA-approved Zepbound starting dose is 2.5 mg once weekly for 4 weeks [1]. | The label says 2.5 mg is for initiation and is not a maintenance dose [1]. |
| Dose increases | The FDA label allows 2.5 mg increases after at least 4 weeks on the current dose [1]. | GI side effects are common during escalation, so tolerability matters [1]. |
| Maintenance doses | The FDA-labeled maintenance doses are 5 mg, 10 mg, or 15 mg once weekly [1]. | Clinicians consider response, side effects, and health history [1]. |
| Maximum dose | The FDA-labeled maximum Zepbound dose is 15 mg once weekly [1]. | Higher doses are not part of the FDA-approved Zepbound schedule [1]. |
| Missed dose window | The FDA label says a missed dose may be administered within 4 days, or 96 hours, after the missed dose [1]. | The label says 2 doses should not be given within 3 days, or 72 hours, of each other [1]. |
What is tirzepatide, and how does it support weight loss?
Tirzepatide is a dual GLP-1/GIP receptor agonist, also called a dual incretin medication, that acts on pathways involved in appetite, food intake, insulin release, and blood sugar regulation [4]. Zepbound is FDA-approved for chronic weight management in eligible adults, while Mounjaro is FDA-approved for type 2 diabetes [1,3].
GLP-1 and GIP dual receptor agonist
GLP-1 means glucagon-like peptide-1, and GIP means glucose-dependent insulinotropic polypeptide. Tirzepatide activates both receptors, which may reduce appetite and food intake while also improving insulin response after meals [4].
In the SURMOUNT-1 trial, adults with obesity or overweight and at least one weight-related condition, but without diabetes, received tirzepatide 5 mg, 10 mg, or 15 mg once weekly or placebo for 72 weeks [2]. Average weight reduction was greater with tirzepatide than placebo, but nausea, diarrhea, constipation, and vomiting were more common; individual results vary [2].
Brand names: Zepbound and Mounjaro vs. compounded tirzepatide
Zepbound (tirzepatide, a dual GLP-1/GIP receptor agonist) is FDA-approved for chronic weight management in eligible adults and for certain adults with obesity and moderate-to-severe obstructive sleep apnea [1]. Mounjaro (tirzepatide, the same active ingredient under a different brand label) is FDA-approved to improve blood sugar control in adults with type 2 diabetes, along with diet and exercise; using Mounjaro only for weight loss is off-label [3].
Compounded tirzepatide via a 503A pharmacy is not FDA-approved and should not be described as a generic, equivalent, or the same as a brand-name product [8]. A 503A pharmacy is a state-licensed pharmacy that may prepare a medication for an individual patient when a licensed clinician writes a prescription for a specific patient need, subject to federal and state rules [8].
What is the standard tirzepatide dosing schedule for weight loss?
The FDA-labeled tirzepatide schedule for Zepbound starts at 2.5 mg once weekly for 4 weeks, then may increase in 2.5 mg steps after at least 4 weeks on the current dose [1]. This section describes the FDA label, not a personal dosing plan.
Starting dose: 2.5 mg weekly
The FDA-approved starting dose for Zepbound is 2.5 mg once weekly for 4 weeks [1]. The label states that the 2.5 mg dose is not approved as a maintenance dose for chronic weight management [1].
Dose escalation: 2.5 mg every 4 weeks
After 4 weeks, the FDA label states that the Zepbound dose should be increased to 5 mg once weekly, and additional 2.5 mg increases may occur after at least 4 weeks on the current dose [1]. This slow escalation is used because gastrointestinal side effects are common, especially during dose changes [1,2].
Maintenance doses: 5, 10, or 15 mg weekly
The FDA-labeled maintenance doses for Zepbound are 5 mg, 10 mg, or 15 mg once weekly [1]. A licensed clinician may consider weight response, nausea, constipation, vomiting, diarrhea, reflux symptoms, diabetes medicines, gallbladder history, and other risks when deciding whether to remain at a dose or consider a label-supported increase [1].
Maximum dose: 15 mg weekly
The FDA-labeled maximum dose for Zepbound is 15 mg once weekly [1]. The same label includes warnings about possible thyroid C-cell tumors, pancreatitis, gallbladder disease, hypoglycemia with insulin or insulin secretagogues, kidney injury, severe gastrointestinal disease, hypersensitivity, and suicidal behavior or thinking [1].
Week-by-week tirzepatide dose chart
This chart shows the FDA-labeled Zepbound titration path, including the 4-week minimum at each dose step before a possible increase [1]. It is a reference chart, not an instruction to change your dose.
| Week range | FDA-labeled dose step | What this step means |
|---|---|---|
| Weeks 1–4 | 2.5 mg once weekly [1] | Initiation dose; not a maintenance dose for chronic weight management [1]. |
| Weeks 5–8 | 5 mg once weekly [1] | First FDA-labeled maintenance dose [1]. |
| Weeks 9–12 | 7.5 mg once weekly, if a clinician determines escalation is appropriate [1] | Intermediate escalation step before 10 mg [1]. |
| Weeks 13–16 | 10 mg once weekly [1] | FDA-labeled maintenance dose [1]. |
| Weeks 17–20 | 12.5 mg once weekly, if a clinician determines escalation is appropriate [1] | Intermediate escalation step before 15 mg [1]. |
| Week 21 and after | 15 mg once weekly [1] | FDA-labeled maintenance dose and maximum weekly dose [1]. |
Is 2.5 mg of tirzepatide enough to lose weight?
Tirzepatide 2.5 mg is the FDA-labeled starting dose for 4 weeks, but the Zepbound label states it is not a maintenance dose for chronic weight management [1]. Clinical trials showing larger average weight changes studied maintenance doses such as 5 mg, 10 mg, and 15 mg once weekly [2].
In SURMOUNT-1, adults without diabetes who received tirzepatide 5 mg, 10 mg, or 15 mg once weekly for 72 weeks had greater average weight reduction than placebo [2]. Side effects such as nausea, diarrhea, constipation, and vomiting were also more common with tirzepatide, and individual results vary [2].
How long does it take to lose weight on tirzepatide?
In major trials, tirzepatide was studied over 72 weeks, so the evidence is based on months of treatment rather than a few days [2,5]. The timeline varies by starting weight, dose reached, tolerability, nutrition, activity, diabetes status, other medicines, and side effects [1,2,5].
Typical timeline in clinical trials
In SURMOUNT-1, adults with obesity or overweight and at least one weight-related condition, excluding diabetes, received tirzepatide 5 mg, 10 mg, or 15 mg once weekly or placebo for 72 weeks [2]. Average body-weight reduction at 72 weeks was greater with tirzepatide than placebo, but gastrointestinal side effects were common and individual results vary [2].
In SURMOUNT-2, adults with obesity or overweight and type 2 diabetes received tirzepatide 10 mg or 15 mg once weekly or placebo for 72 weeks [5]. Average weight reduction was greater with tirzepatide than placebo, but gastrointestinal adverse events were common, and people using insulin or insulin-stimulating medicines may need monitoring for low blood sugar [1,5].
What to expect at each dose step
The first month is mainly an adjustment period under the FDA label [1]. Later dose steps may have stronger appetite effects for some people, but they may also bring more nausea, vomiting, constipation, diarrhea, reflux symptoms, or abdominal pain [1,2].
Questions such as “how long to lose 30 lb on tirzepatide” cannot be answered safely for one person without a clinical evaluation. Trial averages can guide expectations, but they do not predict an individual result, and side effects or contraindications may change the plan [1,2,6].
When and how do I take my weekly injection?
The FDA label describes tirzepatide as a once-weekly subcutaneous injection that may be given at any time of day, with or without meals [1]. Injection timing and technique should follow the medication label, pharmacy label, and clinician instructions.
Same day each week, any time of day
The FDA label says Zepbound is injected once weekly on the same day each week and may be given at any time of day, with or without meals [1]. The label also says the weekly day may be changed if the time between 2 doses is at least 3 days, or 72 hours [1].
Injection sites and technique
The FDA label lists the abdomen, thigh, or upper arm as injection sites for Zepbound and advises rotating the injection site with each dose [1]. The label says Zepbound should not be mixed with insulin in the same injection, and insulin injections should be given in a different area if both are used [1].
Storage of pens and vials
The FDA label says Zepbound should be stored in the refrigerator at 36°F to 46°F and may be stored at room temperature up to 86°F for up to 21 days when needed [1]. Compounded tirzepatide storage instructions can differ by formulation, so the pharmacy label should be followed.
What if I miss a dose of tirzepatide?
The FDA label gives a 4-day, or 96-hour, missed-dose window for tirzepatide [1]. If missed doses happen often, or if there has been a long gap, a clinician can help decide the safest next step.
Under the FDA label, if a Zepbound dose is missed, it may be administered as soon as possible within 4 days, or 96 hours, after the missed dose [1]. If more than 4 days have passed, the label states that the missed dose should be skipped and the next dose administered on the regular weekly schedule [1].
The FDA label states that 2 doses should not be administered within 3 days, or 72 hours, of each other [1]. This matters because stacking doses too close together may worsen side effects such as nausea, vomiting, diarrhea, dehydration, or low blood sugar risk in people using certain diabetes medicines [1].
Does compounded tirzepatide follow the same dosing schedule?
Compounded tirzepatide is not FDA-approved and is not reviewed by FDA for safety, effectiveness, or manufacturing quality before dispensing [8]. Many clinicians reference FDA-labeled tirzepatide schedules, including the 2.5 mg initiation dose, but a compounded medication plan must be prescribed for the individual patient and should not be assumed equivalent to a brand product [1,8].
Compounded medications may be considered when a prescriber determines there is a specific patient need that cannot be met by a commercially available product, subject to federal and state rules [8]. Patients can ask which state-licensed 503A pharmacy prepares the medication and what sterility, potency, and quality checks are used.
What side effects explain why the dose starts low?
Tirzepatide starts low and increases gradually because stomach-related side effects are common, especially during dose escalation [1]. The boxed warning and contraindications also matter before any dose plan is considered, including the warning about thyroid C-cell tumors and contraindication in people with MTC or MEN 2 [1].
Common GI side effects
In the Zepbound label, common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, and gastroesophageal reflux disease symptoms [1]. In SURMOUNT-1, gastrointestinal side effects were more common with tirzepatide than placebo while average weight reduction was also greater with tirzepatide than placebo [2].
The boxed warning states that tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans [1]. Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].
When clinicians may slow titration or reassess treatment
A clinician may slow escalation, pause at a current dose, or reassess treatment if side effects are hard to manage. The FDA label includes warnings for pancreatitis, gallbladder disease, acute kidney injury, severe gastrointestinal disease, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, hypersensitivity, and suicidal behavior or thinking [1].
Urgent medical care is important for severe or lasting abdominal pain, repeated vomiting, signs of dehydration, symptoms of an allergic reaction, or thoughts of self-harm. People using insulin or sulfonylureas may have a higher risk of low blood sugar when tirzepatide is added, so clinicians may need to adjust those medicines [1].
How do I get a tirzepatide prescription and dosing plan?
A safe tirzepatide plan starts with a clinician review of BMI, weight-related conditions, type 2 diabetes status, medications, pregnancy plans, side effect risk, and contraindications such as MTC or MEN 2 [1,6]. For chronic weight management, major guidelines support medication as part of a broader plan that can include nutrition, physical activity, sleep, and behavior support [6,7].
You can seek care through an in-person clinician, an obesity medicine specialist, or a licensed telehealth provider. Chia is one option for clinician-reviewed telehealth access to compounded GLP-1 medications through licensed 503A pharmacy partners when clinically appropriate; compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or manufacturing quality before dispensing [8].
Before starting, ask how the clinician will handle nausea, constipation, missed doses, dose escalation, lab monitoring, drug interactions, pregnancy planning, and when to stop or change therapy. A clear plan matters because the dose that works well for one person may not be the safest choice for another [1,6].
3-min quiz
Want help reviewing your options?
A licensed clinician can review your health history and discuss whether an FDA-approved tirzepatide medication, a compounded GLP-1 option, or another weight-management plan fits your needs. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or manufacturing quality before dispensing.
Frequently asked questions
The FDA-approved Zepbound label lists tirzepatide 2.5 mg once weekly for 4 weeks, then 5 mg once weekly, with possible 2.5 mg increases after at least 4 weeks on the current dose, up to 15 mg once weekly [1]. This is label information, not personal dosing advice.
The FDA-labeled maximum Zepbound dose is 15 mg once weekly [1]. Higher weekly doses are not part of the FDA-approved Zepbound dosing schedule [1].
The FDA label describes 2.5 mg once weekly as the initiation dose for the first 4 weeks and states it is not a maintenance dose for chronic weight management [1]. In SURMOUNT-1, larger average weight-loss results were studied with tirzepatide 5 mg, 10 mg, and 15 mg once weekly, but nausea, diarrhea, constipation, and vomiting were common and individual results vary [2].
The FDA label says tirzepatide dose increases may occur after at least 4 weeks on the current dose [1]. A clinician may keep a person at a dose longer based on side effects, response, contraindications, diabetes medicines, or other safety concerns [1].
The FDA label states that a missed Zepbound dose may be administered within 4 days, or 96 hours, after the missed dose; if more than 4 days have passed, the label says the missed dose should be skipped and the next dose administered on the regular weekly schedule [1]. The label also states that 2 doses should not be administered within 3 days, or 72 hours, of each other [1].
Compounded tirzepatide is not FDA-approved and is not reviewed by FDA for safety, effectiveness, or manufacturing quality before dispensing [8]. A clinician may reference FDA-labeled tirzepatide dosing information, but compounded medication dosing must be prescribed for the individual patient and should not be assumed equivalent to a brand product [1,8].
AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health. A licensed clinician still decides whether treatment is appropriate, and a prescription is not guaranteed.
Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in people with a serious hypersensitivity to tirzepatide or its ingredients [1]. A clinician should also review pregnancy plans, pancreatitis history, gallbladder disease, kidney risk, diabetes medicines, and other safety issues [1].
3-min quiz
Talk with a clinician about dosing
If you are considering tirzepatide, a clinical review can help match the plan to your health history, goals, and side effect risk. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or manufacturing quality before dispensing.
References
- 1.U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, prescribing information. 2025.
- 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- 3.U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, prescribing information. 2024.
- 4.Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018.
- 5.Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2023.
- 6.Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015.
- 7.Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016.
- 8.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
- 9.U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. 2024.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
